Get the Stockscreener App
2.61
13.29%
-0.40
Aprea Therapeutics Inc stock is traded at $2.61, with a volume of 4,000.
It is down -13.29% in the last 24 hours and down -39.30% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$3.01
Open:
$2.922
24h Volume:
4,000
Relative Volume:
0.19
Market Cap:
$16.20M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.472
EPS:
-5.53
Net Cash Flow:
$-12.27M
1W Performance:
-22.09%
1M Performance:
-39.30%
6M Performance:
-48.79%
1Y Performance:
-30.40%
1-Day Range:
$2.90
$3.00
1-Week Range:
$2.865
$3.54
52-Week Range:
$2.1501
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
617-463-9385
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| APRE | 2.9228 | 16.20M | 0 | -14.29M | -12.27M | -5.53 |
| VRTX | 447.61 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.94 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.87 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN
HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN
Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz
Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea therapeutics director sells shares worth $29,583 - Investing.com India
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com
Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK
Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha
Aprea reports safe trial results for new cancer drug - Investing.com
Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News
Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St
Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India
Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com
Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa
Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates - MSN
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia
Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo
Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India
Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):